SciFluor discovers and develops proprietary new chemical entities (NCEs) in multiple therapeutic areas, including ophthalmology, fibrosis and neurology. We work with known biological mechanisms, avoiding the risks and uncertainties associated with novel biological targets. Our core scientific team uses their extensive knowledge and experience to design, synthesize and test fluorine-containing small molecule drug candidates that demonstrate improved potency, selectivity, and pharmacokinetic properties. We then advance drug candidates into early stage clinical studies to establish their potential as best-in-class therapeutics.

Our lead drug, SF0166, has been studied in two separate multi-center, randomized, Phase I/II trials, in patients with Diabetic Macular Edema (DME) (clinicaltrials.gov ID# NCT02914613) and in patients with neovascular age-related macular degeneration (wet-AMD) (clinicaltrials.gov ID# NCT02914639).

SciFluor News

SciFluor Announces Positive Top-Line Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration
read more >

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >